Financings Routine +

AI/ML Innovations Inc. Announces Closing of Final Tranche of Private Placement to Raise $1,917,500

AI/ML Innovations Secures Funding Amidst Dilutive Debt Settlements

By The Northwire Desk — AI Analysis May 11, 2026 · 22:20 AIML · 0.06 AI-ML Innovations Inc.

Executive Summary

Financing Completion: The company closed the second and final tranche of a private placement, raising $1,917,500 in convertible debentures.
Total Capital Raised: Combined with the first tranche ($950,000), total aggregate principal is $2,867,500.
Instrument Terms: Debentures convert into Units at $0.05 per Unit (1 share + 1 warrant). Warrants exercise at $0.15 for 36 months. Interest rate is 10% per annum. Maturity is May 2029.
Insider Participation: Insiders purchased $340,000 of the debentures in this tranche (total insider participation across tranches was ~$890,000).
Regulatory Status: Offering subject to final approval from the Canadian Securities Exchange (CSE).
Debt Settlement Context: This follows a significant debt settlement in April 2026 where 17 million shares were issued at $0.05 to settle ~$855,921 of indebtedness, heavily weighted toward insiders.

Material Impact

Capitalization vs. Dilution: The raise provides essential working capital (~$2.8M total), but the conversion price ($0.05) is below the current trading price ($0.06). This creates immediate dilution pressure if holders convert, though warrants at $0.15 provide a buffer for now.
Expected Nature: The financing was proposed on March 12, 2026, and closed May 11, 2026. As the terms were public months prior, this is not unexpected market-moving information but rather the execution of a known plan.
Insider Alignment vs. Dilution: While insider participation ($890k total) signals confidence, it occurred alongside a massive share issuance for debt settlement (17M shares @ $0.05). The net effect is significant dilution to existing shareholders without immediate revenue offset.
Liquidity Risk Mitigation: The cash infusion extends the runway, reducing near-term bankruptcy risk, but does not solve the fundamental lack of commercial revenue or regulatory clearance for flagship products (CardioYield).

AIML · Price

Company Overview

Core Business: AI/ML Innovations Inc. focuses on digital health platforms converting biometric data into clinical insights via its subsidiary NeuralCloud Solutions.
Flagship Products: MaxYield™ (ECG signal-processing engine) and CardioYield™ (AI-powered Holter reporting software).
Development Stage: Pre-revenue / Pilot Phase. Multiple pilots launched in Jamaica, Canada, and with US partners (Movesense), but no commercial revenue disclosed.
Intellectual Property: Granted U.S. Patent No. 12,465,266 in November 2025 protecting core ECG signal-processing architecture.
Strategic Partnerships: Non-binding agreements with Movesense, Lakeshore Cardiology, Culminate H Labs, and Heartdent Center Ltd.

More from AI-ML Innovations Inc.